| Literature DB >> 33859795 |
Johan J N Veerman1, Yorik B Bruseker2, Eddy Damen2, Erik H Heijne2, Wendy van Bruggen2, Koen F W Hekking2, Rob Winkel2, Christopher D Hupp3, Anthony D Keefe3, Julie Liu4, Heather A Thomson3, Ying Zhang3, John W Cuozzo3, Andrew J McRiner3, Mark J Mulvihill5, Peter van Rijnsbergen2, Birgit Zech6, Louis M Renzetti7, Lee Babiss8, Gerhard Müller6.
Abstract
Herein we report the discovery of 2,4-1H-imidazole carboxamides as novel, biochemically potent, and kinome selective inhibitors of transforming growth factor β-activated kinase 1 (TAK1). The target was subjected to a DNA-encoded chemical library (DECL) screen. After hit analysis a cluster of compounds was identified, which was based on a central pyrrole-2,4-1H-dicarboxamide scaffold, showing remarkable kinome selectivity. A scaffold-hop to the corresponding imidazole resulted in increased biochemical potency. Next, X-ray crystallography revealed a distinct binding mode compared to other TAK1 inhibitors. A benzylamide was found in a perpendicular orientation with respect to the core hinge-binding imidazole. Additionally, an unusual amide flip was observed in the kinase hinge region. Using structure-based drug design (SBDD), key substitutions at the pyrrolidine amide and the glycine resulted in a significant increase in biochemical potency.Entities:
Year: 2021 PMID: 33859795 PMCID: PMC8040042 DOI: 10.1021/acsmedchemlett.0c00547
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345